Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moderna, Inc. (NASDAQ:MRNA) announced the immediate departure of its Chief Financial Officer, Jorge Gomez, amidst an ongoing internal investigation at his previous employer, Dentsply Sirona Inc. In light of this, David Meline, the recently retired CFO, will resume his role as CFO while the company searches for a new candidate. Moderna emphasizes that these changes come with risks and uncertainties, and encourages stakeholders to refer to its latest filings for detailed risk factors.
Positive
- David Meline resumes role as CFO, providing continuity during the transition.
Negative
- Departure of Jorge Gomez may raise concerns about internal governance and financial oversight.
- Ongoing internal investigation at Dentsply Sirona may reflect on Gomez's potential impact on Moderna.
Details
News Market Reaction – MRNA
The recorded move for MRNA in the trading session of this news was -6.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr. Gomez's former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting.
Moderna's recently retired Chief Financial Officer, David Meline, will continue in his role of Chief Financial Officer (CFO) as of May 11 while Moderna reopens its search for a new CFO.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the continuation of David Meline as the Company's Chief Financial Officer. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.
Moderna Contacts
Media:
Colleen Hussey
Senior Director, Corporate Communications
617-335-1374
Colleen.Hussey@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: ModernaTX, Inc
View source version on accesswire.com:
https://www.accesswire.com/700876/Departure-of-Jorge-Gomez-and-Continuation-of-David-Meline-as-Chief-Financial-Officer
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.